PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia Sustained Drug Delivery Technology
18.02.2022 - - Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -ย PolyActiva Pty Ltd, a clinical-stage ... Seite 1
Like Ahmed Michael Coote Prezia Technology University Of Toronto Prezia Sustained Drug Delivery Technology University Of Utah
Source: wallstreet-online.de